Abstract: Objective  To evaluate the efficacy and safety of thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Methods   To review the efficacy and safety of  thalidomide and thalidomide analogues for the treatment of IBD systematically, a systematic research was performed　on PubMed, Cochrane Center Register of Controlled Trails, Embase, Web of Science, CNKI, Wan Fang, CQVIP and other data bases. And analysis was made on its induced remission rate, sustaining remission rate and adverse events. Results  Sixteen studies (3 RCTs and 13 case series) met the inclusion criteria and 333 patients were included. Two RCTs showed that thalidomide can effectively increase induced remission rate in patients  with CD and UC(46.4%  vs  11.5%, P=0.010; 83.3%  vs  18.8%,P=0.005). And a series of case studies revealed that the thalidomide was conducive to the remission of CD, with the induced remission rate was 50.0% (95%CI=36.0%65.0%).  Neurologic disturbances accounted for 65.5% of the adverse events(207/316), being the most common adverse event. Peripheral neuropathy was the most frequent cause of drug withdrawal.Conclusion  Thalidomide is effective for treating IBD,  especially for inducing remission in CD patients.

Key words: inflammatory bowel disease, crohn disease, colitis, ulcerative, thalidomide； metaanalysis